Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879774 | 0.99 | KEAP1 (0.50) | CHRM2CHRM1HRH1KCNH2SLC29A1 | |
| SCHEMBL3044199 | 0.86 | CHRM3 (0.47) | CHRM2CHRM1HRH1KCNH2SLC29A1 | |
| SCHEMBL4887507 | 0.78 | HTT (0.60) | CHRM2CHRM1HRH1KCNH2CYP3A4 | |
| SCHEMBL4885092 | 0.78 | HTT (0.60) | CHRM2CHRM1HRH1KCNH2CYP3A4 | |
| SCHEMBL4889750 | 0.76 | KEAP1 (0.60) | CHRM2CHRM1HRH1KCNH2CYP3A4 | |
| SCHEMBL9193108 | 0.76 | CHRM3 (0.65) | CHRM2CHRM1CYP3A4KEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL9197639 | 0.75 | CHRM3 (0.64) | CHRM2CHRM1LMNACYP3A4KEAP1 | |
| SCHEMBL3049247 | 0.75 | KEAP1 (0.49) | CHRM2CHRM1HRH1KCNH2SLC29A1 | |
| SCHEMBL13592212 | 0.74 | CHRM3 (0.55) | CHRM2CHRM1HRH1KCNH2CYP3A4 | |
| SCHEMBL4886224 | 0.74 | KEAP1 (0.50) | CHRM2CHRM1KEAP1NFE2L2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | claimed |
| CN-101379040-A | Muscarinic receptor antagonists | RANBAXY LAB LTD (IN) | 2009-03-04 | — | — | CN | claimed |
| EP-1968945-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-09-17 | — | — | EP | claimed |
| WO-2007077510-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | claimed |
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-1434765-B1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| CN-101379040-A | Muscarinic receptor antagonists | RANBAXY LAB LTD (IN) | 2009-03-04 | — | — | CN | disclosed |
| EP-1968945-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077510-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222393-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885HRH1 15/4885 |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | HRH3, HRH4, HRH2 | CHRM2 115/4885CHRM1 178/4885HRH1 4/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CHRM2 84/4885CHRM1 158/4885HRH1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.